novartis-infigratinib
Preclinical
Novartisnovartis-infigratinib is one of 26 therapeutic programs targeting Bile Duct Cancer. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
25
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
30 competitors in Bile Duct Cancer
#DrugCompanyPhaseTrials
1Stivarga
BayerApproved
Photofrin
PPinnacle Biologics Inc.
Approved
Ixempra
RR-Pharm
Approved
Gemzar
Johnson & JohnsonPhase 2
Abraxane
Bristol-Myers SquibbPhase 2
Lynparza
AstraZenecaPhase 2
Koselugo
AstraZenecaPhase 2
Keytruda
Merck & Co.Phase 2
Imfinzi
AstraZenecaPhase 2
Taxol
TevaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for novartis-infigratinib. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company